Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Azenta, Inc. - Common Stock (NQ:AZTA)

28.97 -0.06 (-0.21%)
Streaming Delayed Price Updated: 10:54 AM EDT, Aug 11, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Azenta, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
1 Small-Cap Stock to Research Further and 2 We Turn Down
Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on. But the flip side is that these businesses have increased downside... 
Via StockStory
Why Azenta (AZTA) Stock Is Up Today
Shares of life sciences company Azenta (NASDAQ:AZTA) jumped 3.3% in the afternoon session after an upgrade from investment firm Raymond James, which lifted its rating to 'outperform' from 'market... 
Via StockStory
Topics Artificial Intelligence
Azenta (AZTA) Stock Trades Up, Here Is Why
Shares of life sciences company Azenta (NASDAQ:AZTA) jumped 5% in the afternoon session after Raymond James upgraded the stock to 'Outperform' from 'Market Perform' and set a $35 price target. The... 
Via StockStory
Earnings Scheduled For August 5, 2025
 
Via Benzinga
Earnings Scheduled For May 7, 2025
 
Via Benzinga
Insights Ahead: Azenta's Quarterly Earnings
 
Via Benzinga
Azenta (AZTA) Q3 EPS Jumps 36%
Via The Motley Fool
Why Azenta (AZTA) Stock Is Trading Lower Today
Shares of life sciences company Azenta (NASDAQ:AZTA) fell 16.3% in the afternoon session after the company announced mixed third-quarter financial results, where a failure to meet revenue targets... 
Via StockStory
Topics Artificial Intelligence Stocks World Trade
Azenta Inc (NASDAQ:AZTA) Reports Mixed Q3 2025 Earnings: Revenue Miss but EPS Beat
Azenta Inc (AZTA) reported mixed Q3 FY2025 results, missing revenue estimates but beating EPS. The company maintained full-year guidance amid investor caution. 
Via Chartmill
Azenta (NASDAQ:AZTA) Misses Q2 Sales Targets
Life sciences company Azenta (NASDAQ:AZTA) fell short of the market’s revenue expectations in Q2 CY2025, with sales flat year on year at $143.9 million. Its non-GAAP profit of $0.14 per share was in... 
Via StockStory
Azenta (AZTA) Q2 Earnings Report Preview: What To Look For
Life sciences company Azenta (NASDAQ:AZTA) will be reporting results this Tuesday before the bell. Here’s what to look for. 
Via StockStory
Topics Artificial Intelligence Economy World Trade
Fortrea, Azenta, Bio-Techne, 10x Genomics, and Amphastar Pharmaceuticals Stocks Trade Up, What You Need To Know
A number of stocks jumped in the afternoon session after a new trade agreement between the United States and Japan spurred a broad market rally. 
Via StockStory
Topics Stocks World Trade
Stocks making big moves yesterday: Vital Farms, Robinhood, Simmons First National, Medpace, and Azenta
Check out the companies making headlines yesterday: 
Via StockStory
Why Azenta (AZTA) Stock Is Up Today
Shares of life sciences company Azenta (NASDAQ:AZTA) jumped 5.7% in the afternoon session after the investment firm Stephens initiated coverage on the life sciences company. 
Via StockStory
Topics Artificial Intelligence Lawsuit
Repligen, Bruker, Fortrea, Azenta, and Biogen Stocks Trade Down, What You Need To Know
A number of healthcare stocks fell in the afternoon session after several negative developments weighed on the sector. Weakness in managed care providers was a significant factor, with companies like... 
Via StockStory
Topics Lawsuit
Winners And Losers Of Q1: Azenta (NASDAQ:AZTA) Vs The Rest Of The Drug Development Inputs & Services Stocks
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Azenta (NASDAQ:AZTA) and the best and worst... 
Via StockStory
Q1 Earnings Outperformers: Azenta (NASDAQ:AZTA) And The Rest Of The Drug Development Inputs & Services Stocks
Let’s dig into the relative performance of Azenta (NASDAQ:AZTA) and its peers as we unravel the now-completed Q1 drug development inputs & services earnings season. 
Via StockStory
3 Low-Volatility Stocks in the Doghouse
Stability is great, but low-volatility stocks may struggle to deliver market-beating returns over time as they sometimes underperform during bull markets. 
Via StockStory
3 Healthcare Stocks Skating on Thin Ice
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. But speed bumps such as inventory destockings have persisted in the wake of... 
Via StockStory
Topics Stocks
3 of Wall Street’s Favorite Stocks Facing Headwinds
Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remembering that analysts rarely issue sell ratings,... 
Via StockStory
3 Small-Cap Stocks in Hot Water
Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on. But the flip side is that these businesses have increased downside... 
Via StockStory
Waters Corporation, Avantor, Azenta, Bio-Techne, and Elanco Stocks Trade Up, What You Need To Know
A number of stocks jumped in the afternoon session after the major indices popped (Nasdaq +3.4%, S&P 500 +2.5%) in response to the positive outcome of U.S.-China trade negotiations, as both sides... 
Via StockStory
Topics Government Stocks World Trade
AZTA Q1 Earnings Call: Revenue Tops Expectations, Margin Progress Amid Macro Headwinds
Life sciences company Azenta (NASDAQ:AZTA) reported Q1 CY2025 results beating Wall Street’s revenue expectations, with sales up 5.2% year on year to $143.4 million. Its non-GAAP profit of $0.05 per... 
Via StockStory
Topics World Trade
Azenta (NASDAQ:AZTA) Beats Q1 Sales Targets
Life sciences company Azenta (NASDAQ:AZTA) reported Q1 CY2025 results beating Wall Street’s revenue expectations, with sales up 5.2% year on year to $143.4 million. Its non-GAAP profit of $0.07 per... 
Via StockStory
Azenta (AZTA) Q1 Earnings Report Preview: What To Look For
Life sciences company Azenta (NASDAQ:AZTA) will be reporting results tomorrow morning. Here’s what investors should know. 
Via StockStory
2 Cash-Heavy Stocks Worth Your Attention and 1 to Approach with Caution
A surplus of cash can mean financial stability, but it can also indicate a reluctance (or inability) to invest in growth. Some of these companies also face challenges like stagnating revenue, declining... 
Via StockStory
3 Cash-Producing Stocks Facing Headwinds
A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand. 
Via StockStory
3 of Wall Street’s Favorite Stocks in the Doghouse
Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional... 
Via StockStory
3 Reasons AZTA is Risky and 1 Stock to Buy Instead
Shareholders of Azenta would probably like to forget the past six months even happened. The stock dropped 23.7% and now trades at $37.66. This might have investors contemplating their next move. 
Via StockStory
Winners And Losers Of Q4: IQVIA (NYSE:IQV) Vs The Rest Of The Drug Development Inputs & Services Stocks
The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how IQVIA (NYSE:IQV) and the rest... 
Via StockStory
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.